IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting
15. März 2023 14:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that an abstract related to the Company’s DNA-based...
IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
14. Dezember 2022 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
IMUNON Announces Strategic Investment in Transomic Technologies
17. November 2022 08:30 ET
|
Imunon, Inc.
Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE DNA Vaccine Platform IMUNON’s Executive Chairman to join Transomic’s...
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
15. September 2022 08:30 ET
|
Celsion Corporation
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE)...
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
08. August 2022 08:30 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
19. Juli 2022 08:35 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
19. Juli 2022 08:30 ET
|
Celsion Corporation
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on...
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
21. Juni 2022 08:30 ET
|
Celsion Corporation
Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit Full Enrollment Expected by Third Quarter of 2022 LAWRENCEVILLE, N.J., June 21, 2022 (GLOBE NEWSWIRE) --...
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
09. Mai 2022 08:30 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress
21. April 2022 11:30 ET
|
Celsion Corporation
Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus The Goal to Provide Broader Range Protection within a Highly Flexible...